Malate dehydrogenase (MDH, EC 1.1.1.37) catalyzes the reversible reduction of oxaloacetate to malate in the presence of NADH. In eukaryotic cells the enzyme is generally found to be present as two distinct isoenzymes; one form is present in the cellular cytosol and the other is present exclusively in the mitochondria. These 2 isoenzymes form part of a shuttle system (the malate-aspartate shuttle) that functions as the major mechanism for the transportation of reducing equivalents between the cytosol and the mitochondria.
As part of our ongoing studies on the mechansim of action and metabolic function of the malate dehydrogenases , we recently investigated the kinetic properties of the 2 isoenzymes present in rat Novikoff hepatoma tissues. These studies were initiated to evaluate whether or not the enzymes in the malate-asparate shuttle of tumour tissues are structurally and functionally identical to those of normal tissues.
Fresh tumour or liver was homogenized with a glass tissue homogenizer in 0.1 M potassium phosphate buffer, pH 7.5, containing 0.25 M sucrose. The homogenate was centrifuged for 10 min at 10,000 g to remove tissue debris. The supernatant was then centrifuged for 30 min at 20,000 g to obtain a high-speed supernatant that contained the cytoplasmic enzymes. The supernatantant did not contain any isocitrate dehydrogenase activity or transhydrogenase activity and was therefore judged to be free of mitochondrial enzymes. This high-speed supernatant was used without further fractionation for the determination of the cytoplasmic MDH (Weber, 1977) . A second possibility is that the activity results from an enzyme that has some non-specific malate dehydrogenase activity. Lactate dehydrogenase would be a likely candidate for this, since it is closely related to MDH in many respects. However, the possibility that lactate dehydrogenase is acting as a malate dehydrogenase isoenzyme can be ruled out on the following observations: (a) Lactate dehydrogenase activity is electrophoretically distinguishable from MDH activity.
(b) The aberrant activity was undetectable in normal tissues, indicating that the aberrant activity must be present in much higher concentrations in tumour tissues than in normal tissues. We found that the lactate dehydrogenase activity in various tumour tissues tested is not more than 2-5 times higher than that in normal tissues, where it is of course present in appreciable amounts. (c) The KM of lactate dehydrogenase for oxaloacetate varies from 1.75mM at pH 6.0 to 4.9mM at pH 7.4 (Parker & Holbrook, 1981) , which is considerably higher than the value of 1.0 mM at pH 7.0 that we found for the aberrant enzyme. A third possibility is that the oxaloacetate is partially converted to pyruvate by a decarboxylase present in the tumour tissues. The pyruvate thus formed would readily be reduced by the lactate dehydrogenase present in the extracts and thus contribute to the observed decreases in NADH in our assays. The fact that the KM values that we obtained for the MDH from normal tissues (and for tumour tissues at low oxaloacetate concentrations) are similar to the values obtained by others (Englard, 1969; Kitto & Kaplan, 1966) with highly purified MDH indicates that significant decarboxylation of the oxaloacetate is not a problem at the low oxaloacetate concentrations. In fact, if the aberrant activity resulted from the decarboxylation of oxaloacetate to pyruvate, we would in effect have measured the KM of the decarboxylase for oxaloacetate as being 1.0 mM, since the KM of lactate dehydrogenase for pyruvate is very low (Everse & Kaplan, 1973) . The fact that the oxaloacetate concentration in tumour cells as well as normal cells is far below 1 mM again raises a question as to the possible metabolic advantage that such a decarboxylase would provide for the tumour cell.
It is clear that the question addressed by this article must remain unanswered until the enzyme that promotes the aberrant activity has been purified and fully characterized. The finding of an isoenzyme with an increased KM in tumour tissues would not be unique, however. Weber et al. (1964) showed that the phosphoglucomutase in rapidly growing hepatomas has a KM for glucose-i-P that is 3-6 times higher than the KM value found for the normal (liver) enzyme. It is thus possible for certain tumour cells to synthesize enzymes different from those produced by normal cells, thus reflecting changes in genetic expression. More detailed information concerning such changes in enzyme characteristics could be useful both for diagnostic and for chemotherapeutic purposes.
